Photodynamic therapy of Glioblastoma cells using doped conjugated polymer nanoparticles: An in vitro comparative study based on redox status

Caverzán, Matías Daniel; Beaugé, Lucía; Chesta, Carlos A.; Palacios, Rodrigo E.; Ibarra, Luis Exequiel

doi:10.1016/j.jphotobiol.2020.112045

Cited by 28 publications

(27 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Afterwards, cells were irradiated with a MultiLED system (460 ± 20 nm) with an irradiance (flux density) of 68 mW/cm 2 for 10 min (equivalent to a dose of 40 J/cm 2 ). Viability was examined 24 h after illumination using MTT assay as described previously and results were expressed as percentage relative to control cells (cells non-irradiated and without nanoparticles) [ 10 ].…”

Section: Methodsmentioning

confidence: 99%

“…Aimed to this, our group has recently developed metallated porphyrin-doped conjugated polymer nanoparticles (CPNs) for highly efficient photodynamic therapy (PDT), a therapeutic approach of growing interest in the treatment of GBM and the prevention of local tumor recurrence [ 7 ]. These CPNs have been shown to be effective at eliminating glioma tumor cells through ROS-induced apoptotic damage thus highlighting their potential use in photo-assisted treatment of GBM [ 8 , 9 , 10 ]. Owing to their excellent light-harvesting and photoemission properties combined with their amenable surface-functionalization to target specific cells, CPNs have been successfully applied as target-specific labels for both in vitro and in vivo fluorescence imaging and identification of cancer cells.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Iron Oxide Incorporated Conjugated Polymer Nanoparticles for Simultaneous Use in Magnetic Resonance and Fluorescent Imaging of Brain Tumors

et al. 2021

Self Cite

View full text Add to dashboard Cite

Conjugated polymer nanoparticles (CPNs) have emerged as advanced polymeric nanoplatforms in biomedical applications by virtue of extraordinary properties including high fluorescence brightness, large absorption coefficients of one and two-photons, and excellent photostability and colloidal stability in water and physiological medium. In addition, low cytotoxicity, easy functionalization, and the ability to modify CPN photochemical properties by the incorporation of dopants, convert them into excellent theranostic agents with multifunctionality for imaging and treatment. In this work, CPNs were designed and synthesized by incorporating a metal oxide magnetic core (Fe3O4 and NiFe2O4 nanoparticles, 5 nm) into their matrix during the nanoprecipitation method. This modification allowed the in vivo monitoring of nanoparticles in animal models using magnetic resonance imaging (MRI) and intravital fluorescence, techniques widely used for intracranial tumors evaluation. The modified CPNs were assessed in vivo in glioblastoma (GBM) bearing mice, both heterotopic and orthotopic developed models. Biodistribution studies were performed with MRI acquisitions and fluorescence images up to 24 h after the i.v. nanoparticles administration. The resulting IONP-doped CPNs were biocompatible in GBM tumor cells in vitro with an excellent cell incorporation depending on nanoparticle concentration exposure. IONP-doped CPNs were detected in tumor and excretory organs of the heterotopic GBM model after i.v. and i.t. injection. However, in the orthotopic GBM model, the size of the nanoparticles is probably hindering a higher effect on intratumorally T2-weighted images (T2WI) signals and T2 values. The photodynamic therapy (PDT)—cytotoxicity of CPNs was not either affected by the IONPs incorporation into the nanoparticles.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Iron Oxide Incorporated Conjugated Polymer Nanoparticles for Simultaneous Use in Magnetic Resonance and Fluorescent Imaging of Brain Tumors

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a recent work carried out by our laboratory group, the expression level of antioxidant enzymes in GBM biopsies using the TCGA and GTEx database was evaluated. In this context, RNA sequencing expression data of 163 GBM tumors, 518 low-grade glioma, and 207 paired normal tissues were examined and the results indicate that CAT, GSR, and SOD2 expression in GBM samples are remarkably higher than those in normal tissues (Caverzán et al, 2020 (Smith et al, 2007). lines; when the GPX system was inhibited by BCNU, CAT activity would then be important in protecting against peroxide toxicity (Zhong et al, 1999).…”

Section: Oxidative S Tre Ss In G B M and Its Impac T In Pdt Effi C mentioning

confidence: 99%

“…In part, this difference could be attributed to the highest antioxidant enzyme gene expression associated with the minor intracellular ROS level, measured by oxidized DCFDA, which possesses this cell line. Furthermore, CPN‐PDT induced the increase in gene expression of the aforementioned antioxidant enzymes to a greater extent in these cells (Caverzán et al., 2020). Many studies correlated the basal levels of antioxidant enzymes in glioma tumor cells and their impact in the efficacy of therapies that induce ROS damage, for instance Smith et al demonstrated that inhibiting catalase activity by using 3‐amino‐1,2,4‐triazole, an irreversible inhibitor that reduced catalase enzymatic activity, increases intracellular ROS level and also the sensitivity of radiation in 36B10 glioma cells (Smith et al., 2007).…”

Section: Oxidative Stress In Gbm and Its Impact In Pdt Efficacymentioning

confidence: 99%

“…, measured by oxidized DCFDA, which possesses this cell line. Furthermore, CPN-PDT induced the increase in gene expression of the aforementioned antioxidant enzymes to a greater extent in these cells(Caverzán et al, 2020). Many studies correlated the basal levels of antioxidant enzymes in glioma tumor cells and their impact in the efficacy of therapies that induce ROS damage, for instanceSmith et al demonstrated that …”

mentioning

confidence: 99%

See 1 more Smart Citation

Understanding the glioblastoma tumor biology to optimize photodynamic therapy: From molecular to cellular events

Ibarra

Vilchez

Caverzán

et al. 2020

J of Neuroscience Research

Self Cite

View full text Add to dashboard Cite

Gliomas are malignant tumors that originate in the central nervous system (CNS). Any tumor that forms in glial cells, or in supporting tissue of the brain is called a glioma. Glioblastoma (GBM) is a subtype of glioma that tends to grow rapidly, spread to other tissues, and has a poor prognosis. GBM is the most aggressive and the most common adult primary intracranial neoplasm (Delgado-Martín & Medina, 2020; Louis et al., 2016). GBM is more common in people ages 50 to 70 and is more prevalent in men than women (Louis et al., 2016). The symptoms or signs of the presence of this type of tumor are: increased pressure on the brain, headaches, seizures, memory loss, and behavioral changes (Sizoo et al., 2010). GBM was previously known as glioblastoma multiforme and the term "multiform" refers to the tumor heterogeneity (Sturm et al., 2014). GBMs may have originated from different kinds of cells, such as astrocytes and oligodendrocytes. The histological features that distinguish GBM from all the other gliomas are the presence of necrosis (dead cells) and the increase in blood vessels around the tumor (D'Alessio et al., 2019). The World Health

show abstract

Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies

Liu

Wang

et al. 2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) represents the most common and fatal form of primary invasive brain tumors as it affects a great number of patients each year and has a median overall survival of approximately 14.6 months after diagnosis. Despite intensive treatment, almost all patients with GBM experience recurrence, and their 5‐year survival rate is approximately 5%. At present, the main clinical treatment strategy includes surgical resection, radiotherapy, and chemotherapy. However, tumor heterogeneity, blood–brain barrier, glioma stem cells, and DNA damage repair mechanisms hinder efficient GBM treatment. The emergence of nanometer‐scale diagnostic and therapeutic approaches in cancer medicine due to the establishment of nanotechnology provides novel and promising tools that will allow us to overcome these difficulties. This review summarizes the application and recent progress in nanotechnology‐based monotherapies (e.g., chemotherapy) and combination cancer treatment strategies (chemotherapy‐based combined cancer therapy) for GBM and describes the synergistic enhancement between these combination therapies as well as the current standard therapy for brain cancer and its deficiencies. These combination therapies that can reduce individual drug‐related toxicities and significantly enhance therapeutic efficiency have recently undergone rapid development. The mechanisms underlying these different nanotechnology‐based therapies as well as the application of nanotechnology in GBM (e.g., in photodynamic therapy and chemodynamic therapy) have been systematically summarized here in an attempt to review recent developments and to identify promising directions for future research. This review provides novel and clinically significant insights and directions for the treatment of GBM, which is of great clinical importance. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Diagnostic Tools > In Vivo Nanodiagnostics and Imaging

show abstract

Photodynamic therapy of Glioblastoma cells using doped conjugated polymer nanoparticles: An in vitro comparative study based on redox status

Cited by 28 publications

References 54 publications

Iron Oxide Incorporated Conjugated Polymer Nanoparticles for Simultaneous Use in Magnetic Resonance and Fluorescent Imaging of Brain Tumors

Iron Oxide Incorporated Conjugated Polymer Nanoparticles for Simultaneous Use in Magnetic Resonance and Fluorescent Imaging of Brain Tumors

Understanding the glioblastoma tumor biology to optimize photodynamic therapy: From molecular to cellular events

Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies

Contact Info

Product

Resources

About